CRYOPORT, INC. (CYRX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $51.00K; Additional Paid in CapitalUSD $1.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.45M; Retained Earnings (Accumulated Deficit)USD $-707.68M.
- 2026-03-31: Common Stock, Value, IssuedUSD $50.00K; Additional Paid in CapitalUSD $1.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.21M; Retained Earnings (Accumulated Deficit)USD $-699.43M.
- 2025-12-31: Common Stock, Value, IssuedUSD $50.00K; Additional Paid in CapitalUSD $1.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.48M; Retained Earnings (Accumulated Deficit)USD $-688.88M.
- 2025-09-30: Common Stock, Value, IssuedUSD $50.00K; Additional Paid in CapitalUSD $1.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.07M; Retained Earnings (Accumulated Deficit)USD $-675.24M.
CRYOPORT, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock Acquired, Average Cost Per Share USD/shares | Preferred Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Value USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $51.00K | $1.15B | $-2.45M | $-707.68M | $490.70M | 3 month · $2.40M 6 month · $4.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $50.00K | $1.15B | $-3.21M | $-699.43M | $494.99M | 3 month · $2.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $50.00K | $1.15B | $-3.48M | $-688.88M | $502.64M | 12 month · $11.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $50.00K | $1.15B | $-4.07M | $-675.24M | $513.27M | 3 month · $2.53M 9 month · $8.60M | 3 month · 7.73 9 month · 7.18 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $50.00K | $1.15B | $-5.40M | $-668.24M | $519.08M | 3 month · $2.37M 6 month · $6.08M | 1 month · 6.76 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $50.00K | $1.15B | $-15.74M | $-769.16M | $398.81M | 3 month · $3.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $50.00K | $1.15B | $-20.93M | $-757.17M | $401.90M | 12 month · $19.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $49.00K | $1.14B | $-16.38M | $-738.50M | $418.57M | 3 month · $4.84M 9 month · $15.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $49.00K | $1.14B | $-29.19M | $-739.30M | $400.10M | 3 month · $5.00M 6 month · $10.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $49.00K | $1.14B | $-30.08M | $-661.31M | $472.19M | 3 month · $5.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $49.00K | $1.13B | $-26.07M | $-642.42M | $489.02M | 12 month · $22.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $49.00K | $1.13B | $-34.10M | $-580.03M | $537.53M | 3 month · $5.98M 9 month · $16.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $49.00K | $1.12B | $-34.49M | $-566.76M | $544.25M | 3 month · $5.80M 6 month · $10.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $48.00K | (m) | (m) | $-548.41M | $560.52M | 3 month · $5.18M | 3 month · 23.63 | (m) | $1.12B | (m) | $560.52M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $48.00K | $1.11B | $-34.55M | $-542.83M | $555.84M | 12 month · $20.08M | 12 month · 23.63 | (m) | $1.11B | $37.90M | $555.84M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $49.00K | (m) | (m) | $-503.79M | $555.72M | 3 month · $5.37M 9 month · $14.75M | 9 month · 24.84 | (m) | $1.09B | (m) | $555.72M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $49.00K | (m) | (m) | $-498.47M | $568.42M | 3 month · $5.26M 6 month · $9.38M | 6 month · 24.84 | (m) | $1.08B | (m) | $568.42M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $50.00K | (m) | (m) | $-489.29M | $609.43M | 3 month · $4.12M | 3 month · 27.24 | (m) | $1.10B | (m) | $609.43M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $50.00K | (m) | (m) | $-467.54M | $641.83M | 12 month · $15.33M | (m) | (m) | $1.10B | (m) | $641.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $46.00K | (m) | $173.00K | $-207.46M | $647.23M | 3 month · $4.15M 9 month · $11.15M | (m) | (m) | $846.19M | (m) | $647.23M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $46.00K | (m) | $1.10M | $-200.93M | $648.03M | 3 month · $4.03M 6 month · $7.00M | (m) | (m) | $841.54M | (m) | $648.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $45.00K | (m) | $880.00K | $-195.54M | $647.27M | 3 month · $2.98M | (m) | (m) | $837.62M | (m) | $647.27M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $40.00K | (m) | $5.38M | $-192.01M | $382.70M | 12 month · $8.83M | (m) | (m) | $566.45M | (m) | $382.70M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $38.98K | (m) | $206.63K | $-180.48M | $120.04M | 3 month · $2.41K 9 month · $6.29M | (m) | (m) | $300.27M | (m) | $120.04M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $38.56K | (m) | $260.20K | $-169.07M | $126.66M | 3 month · $2.28M 6 month · $3.88M | (m) | (m) | $295.42M | (m) | $126.66M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $37.93K | (m) | $423.21K | $-163.26M | $127.30M | 3 month · $1.60M | (m) | (m) | $290.11M | (m) | $127.30M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $37.00K | (m) | $-45.00K | $-159.32M | $126.28M | 12 month · $6.87M | (m) | (m) | $285.61M | (m) | $126.28M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $35.84K | (m) | $-66.00K | $-158.37M | $110.33M | 3 month · $1.93M 9 month · $5.28M | (m) | (m) | $268.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $35.49K | (m) | $38.30K | $-145.90M | $108.75M | 3 month · $1.96M 6 month · $3.36M | (m) | (m) | $254.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $30.68K | (m) | $20.85K | $-143.38M | $38.91M | 3 month · $1.40M | (m) | (m) | $182.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $30.32K | (m) | $3.15K | $-140.99M | $38.55M | 12 month · $5.41M | (m) | (m) | $179.50M | (m) | $38.55M | (m) | 12 month · $191.67K | (m) | (m) | (m) |
| 2018-09-30 | $29.21K | (m) | $-43.42K | $-138.73M | $29.08M | 3 month · $1.48M 9 month · $3.94M | (m) | (m) | $167.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $28.45K | (m) | (m) | $-136.59M | $24.42M | 3 month · $1.43M 6 month · $2.46M | (m) | (m) | $160.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $27.59K | (m) | (m) | $-134.12M | $22.45M | 3 month · $1.03M | (m) | (m) | $156.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $25.70K | (m) | $0.00 | $-131.43M | $17.89M | 12 month · $3.48M | (m) | (m) | $149.29M | (m) | (m) | (m) | 12 month · $170.33K | (m) | (m) | (m) |
| 2017-09-30 | $25.22K | (m) | (m) | $-129.16M | $17.75M | (m) | (m) | (m) | $146.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $23.99K | (m) | (m) | $-127.18M | $15.03M | (m) | (m) | (m) | $142.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $23.94K | (m) | (m) | $-125.32M | $16.07M | (m) | (m) | (m) | $141.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $17.60K | (m) | (m) | $-123.53M | $5.68M | 9 month · $2.28M | (m) | (m) | $129.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $15.13K | (m) | (m) | $-119.25M | $3.70M | (m) | (m) | (m) | $122.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $15.12K | (m) | (m) | $-117.07M | $5.09M | (m) | (m) | (m) | $122.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $12.25K | (m) | (m) | $-113.13M | $3.10M | 12 month · $2.57M | (m) | (m) | $116.21M | (m) | (m) | (m) | (m) | 12 month · $521.06K | (m) | (m) |
| 2015-12-31 | $7.25K | (m) | (m) | $-109.35M | $4.99M | (m) | (m) | (m) | $114.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $7.17K | (m) | (m) | $-106.59M | $6.72M | (m) | (m) | (m) | $113.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $5.07K | (m) | (m) | $-104.17M | $2.05M | (m) | (m) | (m) | $106.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $5.03K | (m) | (m) | $-97.77M | $-416.30K | 12 month · $864.31K | (m) | (m) | $97.35M | (m) | (m) | (m) | (m) | 12 month · $826.92K | 12 month · $458.94K | (m) |
| 2014-12-31 | $60.06K | (m) | (m) | $-93.93M | $-1.12M | (m) | (m) | (m) | $92.75M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $60.06K | (m) | (m) | $-92.03M | $-1.37M | (m) | (m) | (m) | $90.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $60.04K | (m) | (m) | $-88.92M | $-1.06M | (m) | (m) | (m) | $87.80M | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $1.95M |
| 2014-03-31 | $5.00K | (m) | (m) | $-85.88M | $-2.30M | 12 month · $678.12K | (m) | (m) | $83.57M | (m) | (m) | (m) | (m) | (m) | 12 month · $478.23K | (m) |
| 2013-12-31 | $59.25K | (m) | (m) | $-84.43M | $-1.40M | (m) | (m) | $0.00 | $82.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $58.15K | (m) | (m) | $-82.59M | $-577.88K | (m) | (m) | $0.00 | $81.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $38.26K | (m) | (m) | $-67.63M | $-3.02M | (m) | (m) | $0.00 | $64.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $37.76K | (m) | (m) | $-66.31M | $-2.06M | 12 month · $693.18K | (m) | $0.00 | $64.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $37.76K | (m) | (m) | $-64.59M | $-550.73K | (m) | (m) | (m) | $64.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $37.76K | (m) | (m) | $-63.03M | $776.49K | (m) | (m) | (m) | $63.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $37.76K | (m) | (m) | $-61.47M | $2.26M | (m) | (m) | (m) | $63.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $37.76K | (m) | (m) | $-59.93M | $3.73M | 12 month · $281.55K | (m) | $0.00 | $63.62M | (m) | (m) | (m) | (m) | (m) | 12 month · $157.00K | (m) |
| 2011-12-31 | $28.28K | (m) | (m) | $-58.26M | $620.87K | (m) | (m) | (m) | $58.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | $28.13K | (m) | (m) | $-56.18M | $2.50M | (m) | (m) | (m) | $58.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $27.71K | (m) | (m) | $-54.15M | $4.09M | (m) | (m) | (m) | $58.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | $27.50K | (m) | (m) | $-52.10M | $5.95M | 12 month · $971.16K | (m) | (m) | $58.02M | (m) | (m) | 12 month · $128.28K | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | $-914.58K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |